Sensus Healthcare, Inc. (NASDAQ:SRTS) Stake Boosted by Sheaff Brock Investment Advisors LLC

view original post

Sheaff Brock Investment Advisors LLC grew its stake in shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) by 59.8% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 26,714 shares of the company’s stock after acquiring an additional 10,000 shares during the period. Sheaff Brock Investment Advisors LLC owned 0.16% of Sensus Healthcare worth $96,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Morgan Stanley boosted its holdings in Sensus Healthcare by 340.4% in the first quarter. Morgan Stanley now owns 44,894 shares of the company’s stock worth $172,000 after purchasing an additional 34,699 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Sensus Healthcare by 18.1% in the second quarter. Geode Capital Management LLC now owns 69,332 shares of the company’s stock worth $266,000 after purchasing an additional 10,616 shares in the last quarter. Finally, Financial Engines Advisors L.L.C. boosted its holdings in Sensus Healthcare by 13.0% in the second quarter. Financial Engines Advisors L.L.C. now owns 81,390 shares of the company’s stock worth $313,000 after purchasing an additional 9,366 shares in the last quarter. Institutional investors and hedge funds own 12.84% of the company’s stock.

A number of equities research analysts recently issued reports on the stock. TheStreet upgraded shares of Sensus Healthcare from a “d+” rating to a “c-” rating in a report on Friday, November 5th. HC Wainwright boosted their target price on shares of Sensus Healthcare from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, December 2nd. Zacks Investment Research raised shares of Sensus Healthcare from a “hold” rating to a “strong-buy” rating and set a $4.75 target price for the company in a research report on Wednesday, November 10th. Finally, Maxim Group reissued a “buy” rating and set a $7.00 target price on shares of Sensus Healthcare in a research report on Friday, November 5th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $6.94.

Shares of NASDAQ:SRTS opened at $8.16 on Tuesday. Sensus Healthcare, Inc. has a 12 month low of $3.08 and a 12 month high of $8.55. The stock’s fifty day moving average is $5.81. The firm has a market capitalization of $135.59 million, a price-to-earnings ratio of -408.00 and a beta of 0.42.

Sensus Healthcare (NASDAQ:SRTS) last released its earnings results on Thursday, November 4th. The company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.02. The business had revenue of $5.53 million during the quarter, compared to the consensus estimate of $5.38 million. Sensus Healthcare had a negative net margin of 0.95% and a negative return on equity of 0.87%. During the same quarter last year, the firm earned ($0.10) earnings per share. Equities research analysts expect that Sensus Healthcare, Inc. will post -0.02 EPS for the current year.

In other Sensus Healthcare news, CEO Joseph C. Sardano sold 21,930 shares of Sensus Healthcare stock in a transaction dated Thursday, December 9th. The shares were sold at an average price of $7.79, for a total value of $170,834.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Joseph C. Sardano sold 10,926 shares of Sensus Healthcare stock in a transaction dated Thursday, December 16th. The stock was sold at an average price of $7.02, for a total transaction of $76,700.52. The disclosure for this sale can be found here. In the last three months, insiders sold 89,668 shares of company stock valued at $670,220. Insiders own 24.30% of the company’s stock.

Sensus Healthcare Profile

Sensus Healthcare, Inc operates as a medical device company, which provides treatments for both oncological and non-oncological skin conditions. The firm’s portfolio of treatment devices includes the SRT-100, SRT-100+, and SRT-100 Vision. Its main product superficial radiation therapy (SRT), a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers, and other skin conditions, such as keloids.

Featured Article: How is the Producer Price Index calculated?

Want to see what other hedge funds are holding SRTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sensus Healthcare, Inc. (NASDAQ:SRTS).

Want More Great Investing Ideas?